These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6489325)

  • 21. Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials.
    Piddock LJ; Diver JM; Wise R
    Eur J Clin Microbiol; 1986 Aug; 5(4):411-5. PubMed ID: 3758052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of the new 4-quinolone compound Ro 23-6240.
    Clarke AM; Zemcov SJ
    Eur J Clin Microbiol; 1987 Apr; 6(2):161-4. PubMed ID: 3109895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the emergence of resistance to lomefloxacin in vitro.
    Kanematsu M; Greenwood D
    Eur J Clin Microbiol Infect Dis; 1989 Aug; 8(8):741-5. PubMed ID: 2506046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective.
    Thomson CJ
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():31-40. PubMed ID: 10225569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The comparative in-vitro activity of pefloxacin.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():1-10. PubMed ID: 2940213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross resistance of quinolone derivatives in gram-negative bacteria.
    Barba D; Pennucci C; Esposito S; Galante D
    Chemioterapia; 1985 Apr; 4(2):192-6. PubMed ID: 3159488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Norfloxacin treatment of acute cystitis in the female and bacterial prostatitis].
    Bischoff W
    Fortschr Med; 1985 Feb; 103(8):225-8. PubMed ID: 3156797
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
    Forsgren A
    Scand J Infect Dis; 1985; 17(1):91-4. PubMed ID: 3158070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].
    Thabaut A; Durosoir JL
    Pathol Biol (Paris); 1982 Jun; 30(6):394-7. PubMed ID: 6810283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.
    Van Caekenberghe DL; Pattyn SR
    Antimicrob Agents Chemother; 1984 Apr; 25(4):518-21. PubMed ID: 6732221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vitro antibacterial activity of a new fluoroquinolone, fleroxacin as a function of the sensitivity or resistance to nalidixic acid and to pefloxacin].
    Soussy CJ; Leclercq R; Deforges L; Duval J
    Pathol Biol (Paris); 1989 May; 37(5):364-9. PubMed ID: 2506511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Nitrofurans: a modern treatment for uncomplicated urinary infections?].
    Cahen P; Honderlick P
    Pathol Biol (Paris); 2000 Jun; 48(5):470-1. PubMed ID: 10949843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of the new fluoroquinolone BMY-40062.
    Chin NX; Neu H
    Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):620-4. PubMed ID: 2120060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of ciprofloxacin against resistant clinical isolates.
    Kelley SG; Bertram MA; Young LS
    J Antimicrob Chemother; 1986 Mar; 17(3):281-6. PubMed ID: 2939048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens.
    Hoogkamp-Korstanje JA; van Oort HJ; Schipper JJ; van der Wal T
    J Antimicrob Chemother; 1984 Dec; 14(6):641-5. PubMed ID: 6440885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.